ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.
Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.
The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.
Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.
Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.
Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.
Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.
Review the full list of eczema resources for your patients shared during National Eczema Awareness Month.
Click here to answer today's poll.
If you weren’t able to attend the 2023 Society of Dermatology Physicians Fall Conference or want to review our latest coverage and interviews, our full recap has you covered.
A new AI platform empowers health care practitioners in numerous specialties to make informed decisions and provide high-quality care to patients with scabies.
From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skin care.
Secukinumab is currently the only IL-17A inhibitor approved for the condition.
Learn more about the in-depth topics covered in the October 2023 print issue of Dermatology Times.
Susan C. Taylor, MD, and George Han, MD, PhD, discuss how to measure treatment response in patients with vitiligo and share advice for counseling patients about long-term use and compliance of treatment.
Experts in dermatological conditions provide insight on challenges patients and clinicians may face in accessing vitiligo medications, especially for newer therapies, and the future of vitiligo treatment.
A comparative study revealed that color constancy algorithms reduce the variability of dermoscopy image quality, leading to positive outcomes for practitioners.
ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.
Ted Lain, MD & MBA, FAAD, provides an overview of a dinner discussion centered around a challenging case of a 28-year-old female experiencing recurrent flaring atopic dermatitis. He shares insights from a panel of dermatologists regarding their recommended treatment approach, emphasizing the incorporation of a novel topical treatment to achieve enduring disease remission.
An expert in dermatology presents the case of a 58-year-old male who has struggled with long-standing atopic dermatitis. The presentation delves into the considerations between topical and systemic treatments and sheds light on the intricacies of managing patients with comorbidities, extensive treatment histories, and the challenges posed by prior authorizations.
The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.
In this week’s Pointers With Portela, the 208SkinDoc explains the hidden risks associated with hair transplants.
Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.
Click here to answer this week's skin cancer poll.
Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.
Authors of the case report that little is known about the associations between psoriasis and renal function.
The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.
Delgocitinib is first-in-class pan-Janus kinase inhibitor.
Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.
PASI scores were significantly correlated with sleep quality, duration, and disturbances.
The Sun Pharma survey included 1003 respondents with mild to moderate acne.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.